Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 461,285	$ 474,019
Restricted cash	20,000	20,000
Accounts receivable	156,270	19,748
Prepaid & other current assets	56,881	101,869
Total current assets	694,436	615,636
Development equipment, net of depreciation of $106,884 and $101,810	5,074	10,148
Intangibles, net of accumulated amortization of $162,655 and $136,974	847,525	873,206
In process R&D	1,101,760	1,101,760
Goodwill	21,062,455	21,062,455
Total assets	23,711,250	23,663,205
Current liabilities:
Accounts payable and accrued liabilities	4,149,412	2,735,805
Accounts payable to related party	322,995	391,631
Contingent Consideration	2,625,000	2,625,000
Derivative liability on Notes	538,610	777,024
Convertible debt for clinical trial	2,040,329	2,000,000
Convertible debt, net of costs	1,658,262	1,091,612
Convertible debt, related party, net of costs	645,947	297,989
Private Placement convertible note, net of costs	1,798,801	943,586
Private Placement convertible note, related party, net of costs	93,488	67,992
Payroll Protection Plan loan	252,973	251,733
Total current liabilities	14,125,817	11,182,372
Commitments and contingencies (Note 12)
Stockholders’ equity:
Convertible Preferred stock, $0.01 par value, 15,000,000 shares authorized; 0 and 278,188 shares issued and outstanding		2,782
Common stock, $.01 par value; 150,000,000 shares authorized; 370,096,959 and 90,601,912 issued and outstanding, respectively	3,700,969	906,019
Additional paid-in capital	32,876,120	32,493,086
Accumulated deficit	(27,664,368)	(21,630,008)
Total Oncotelic Therapeutics, Inc. stockholders’ equity	8,912,721	11,771,879
Non-controlling interests	672,712	708,954
Total stockholders’ equity	9,585,433	12,480,833
Total liabilities and stockholders’ equity	$ 23,711,250	$ 23,663,205